Curevac has filed a patent for a vaccine/inhibitor combination that includes an RNA vaccine and a PD-1 pathway inhibitor. The invention is aimed at preventing or treating tumor or cancer diseases, as well as infectious diseases. The patent also covers the use of an RNA vaccine in therapy with a PD-1 pathway inhibitor. GlobalData’s report on Curevac gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Curevac NV - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Curevac, personalized cancer vaccines was a key innovation area identified from patents. Curevac's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.

Rna vaccine combined with pd-1 pathway inhibitor for disease treatment

Source: United States Patent and Trademark Office(USPTO). Credit: Curevac NV

A recently filed patent (Publication Number: US20230158131A1) describes a method for treating cancer by administering an immunogenic composition and a PD-1 pathway inhibitor to a subject. The immunogenic composition includes mRNA encoding at least one epitope of a tumor-specific antigen (TSA), and the mRNA is provided in complex with a cationic or polycationic carrier. The PD-1 pathway inhibitor is an antagonistic antibody that binds to PD-1.

The method can be used for subjects who have previously been administered a PD-1 pathway inhibitor. The PD-1 pathway inhibitor can be administered before the immunogenic composition, and the two can be administered sequentially or concurrently. The method is applicable to subjects with various types of cancer, including melanoma and metastatic solid tumors.

The administration of the immunogenic composition can be done subcutaneously, intravenously, intradermally, or intramuscularly. The PD-1 pathway inhibitor is administered intravenously. The immunogenic composition may contain mRNA encoding at least two epitopes of the TSA, or at least two epitopes from different TSAs. The epitopes of the different TSAs can be encoded on the same mRNA molecule. The immunogenic composition may also contain mRNA encoding three, four, five, or more epitopes from different TSAs.

Specific examples of TSAs mentioned in the patent include NY-ESO-1 and MAGE-A3. The mRNA used in the immunogenic composition may have modifications of nucleobases, and the carrier may be a cationic or polycationic lipid.

This patent provides a method for treating cancer by combining an immunogenic composition and a PD-1 pathway inhibitor. The use of mRNA encoding tumor-specific antigens and a cationic or polycationic carrier enhances the immunogenicity of the composition. The method can be used in subjects who have previously received a PD-1 pathway inhibitor and can be administered sequentially or concurrently. The patent covers various types of cancer, and the immunogenic composition can be administered through different routes. The inclusion of multiple epitopes from different TSAs further enhances the effectiveness of the treatment.

To know more about GlobalData’s detailed insights on Curevac, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies